$3396 | SAVE $599 | Single User
$6792 | SAVE $1,198 | Site License
$10187 | SAVE $1,798 | Enterprise License

Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

Published by GBI Research: 01 Jul 2017 | 100094 | In Stock

Introduction

Transplantation Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the transplantation pipeline landscape, specifically covering drugs used to prevent and treat organ rejection and graft-versus-host disease. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), and the rejection of bone, liver, kidney, lung and heart transplants.

Transplant rejection is a complication that can occur after the replacement of a defective host organ with a foreign donor organ. General risks associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Additionally, following a transplant, the immune system may consider the transplanted heart as foreign and mount a response against it, especially if the antigens expressed by the tissues in each do not match. Generally, immunosuppressive drugs are administered simultaneously with the transplant in order to minimize this risk. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

The size of these pipelines ranges from seven products in heart transplantation to 121 in bone marrow transplantation. A wide range of targets, including integrins, chemokine receptors, protein kinases and cadherins are being developed, with no particular class of target predominating in terms of pipeline volume within each indication. However, there is a clear trend towards immune system molecular targets being studied, reflecting the underlying immune-based pathophysiology of these indications.

Scope

- Which companies are the most active within the pipeline for transplantation therapeutics?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in the field of transplantation therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents
for Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

  • Table of Contents

    GBI Research Report Guidance 2

    Executive Summary 3

    Table of Contents 4

    List of Tables 6

    List of Figures 12

    Introduction 14

    Transplantation Report Coverage 14

    Bone Marrow Transplant Rejection - Overview 14

    Graft Versus Host Disease (GVHD) - Overview 14

    Liver Transplant Rejection - Overview 14

    Kidney Transplant Rejection - Overview 14

    Lung Transplant Rejection - Overview 14

    Heart Transplant Rejection - Overview 15

    Therapeutics Development 16

    Bone Marrow Transplant Rejection 16

    Graft Versus Host Disease (GVHD) 27

    Liver Transplant Rejection 38

    Kidney Transplant Rejection 42

    Lung Transplant Rejection 48

    Heart Transplant Rejection 51

    Therapeutics Assessment 52

    Bone Marrow Transplant Rejection 52

    Graft Versus Host Disease (GVHD) 62

    Liver Transplant Rejection 72

    Kidney Transplant Rejection 80

    Lung Transplant Rejection 88

    Heart Transplant Rejection 96

    Companies Involved in Therapeutics Development 104

    Bone Marrow Transplant Rejection 104

    Graft Versus Host Disease (GVHD) 139

    Liver Transplant Rejection 170

    Kidney Transplant Rejection 173

    Lung Transplant Rejection 185

    Heart Transplant Rejection 187

    Dormant Projects 189

    Bone Marrow Transplant Rejection 189

    Graft Versus Host Disease (GVHD) 192

    Liver Transplant Rejection 195

    Kidney Transplant Rejection 196

    Lung Transplant Rejection 198

    Heart Transplant Rejection 198

    Discontinued Products 199

    Bone Marrow Transplant Rejection 199

    Graft Versus Host Disease (GVHD) 199

    Liver Transplant Rejection 200

    Kidney Transplant Rejection 200

    Product Development Milestones 201

    Bone Marrow Transplant Rejection 201

    Graft Versus Host Disease (GVHD) 212

    Liver Transplant Rejection 223

    Kidney Transplant Rejection 225

    Lung Transplant Rejection 234

    Appendix 241

    Methodology 241

    Coverage 241

    Secondary Research 241

    Primary Research 241

    Expert Panel Validation 241

    Contact Us 241

    Disclaimer 242

List Of Tables
in Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

List of Tables

Number of Products under Development for Bone Marrow Transplant Rejection 16

Number of Products under Development by Companies, Bone Marrow Transplant Rejection 18

Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection 21

Products under Development by Companies, Bone Marrow Transplant Rejection 22

Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection 26

Number of Products under Development for Graft Versus Host Disease (GVHD) 27

Number of Products under Development by Companies, Graft Versus Host Disease (GVHD) 29

Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 32

Products under Development by Companies, Graft Versus Host Disease (GVHD) 33

Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 37

Number of Products under Development for Liver Transplant Rejection 38

Number of Products under Development by Companies, Liver Transplant Rejection 39

Number of Products under Development by Universities/Institutes, Liver Transplant Rejection 40

Products under Development by Companies, Liver Transplant Rejection 41

Products under Development by Universities/Institutes, Liver Transplant Rejection 41

Number of Products under Development for Kidney Transplant Rejection 42

Number of Products under Development by Companies, Kidney Transplant Rejection 44

Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 45

Products under Development by Companies, Kidney Transplant Rejection 46

Products under Development by Universities/Institutes, Kidney Transplant Rejection 47

Number of Products under Development for Lung Transplant Rejection 48

Number of Products under Development by Companies, Lung Transplant Rejection 49

Products under Development by Companies, Lung Transplant Rejection 50

Number of Products under Development for Heart Transplant Rejection 51

Number of Products under Development by Companies, Heart Transplant Rejection 51

Products under Development by Companies, Heart Transplant Rejection 51

Number of Products by Stage and Target, Bone Marrow Transplant Rejection 53

Number of Products by Stage and Mechanism of Action, Bone Marrow Transplant Rejection 56

Number of Products by Stage and Route of Administration, Bone Marrow Transplant Rejection 59

Number of Products by Stage and Molecule Type, Bone Marrow Transplant Rejection 61

Number of Products by Stage and Target, Graft Versus Host Disease (GVHD) 63

Number of Products by Stage and Mechanism of Action, Graft Versus Host Disease (GVHD) 66

Number of Products by Stage and Route of Administration, Graft Versus Host Disease (GVHD) 69

Number of Products by Stage and Molecule Type, Graft Versus Host Disease (GVHD) 71

Number of Products by Stage and Target, Liver Transplant Rejection 73

Number of Products by Stage and Mechanism of Action, Liver Transplant Rejection 75

Number of Products by Stage and Route of Administration, Liver Transplant Rejection 77

Number of Products by Stage and Molecule Type, Liver Transplant Rejection 79

Number of Products by Stage and Target, Kidney Transplant Rejection 81

Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection 83

Number of Products by Stage and Route of Administration, Kidney Transplant Rejection 85

Number of Products by Stage and Molecule Type, Kidney Transplant Rejection 87

Number of Products by Stage and Target, Lung Transplant Rejection 89

Number of Products by Stage and Mechanism of Action, Lung Transplant Rejection 91

Number of Products by Stage and Route of Administration, Lung Transplant Rejection 93

Number of Products by Stage and Molecule Type, Lung Transplant Rejection 95

Number of Products by Stage and Target, Heart Transplant Rejection 97

Number of Products by Stage and Mechanism of Action, Heart Transplant Rejection 99

Number of Products by Stage and Route of Administration, Heart Transplant Rejection 101

Number of Products by Stage and Molecule Type, Heart Transplant Rejection 103

Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc 104

Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc 104

Bone Marrow Transplant Rejection - Pipeline by Actelion Ltd 105

Bone Marrow Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc 105

Bone Marrow Transplant Rejection - Pipeline by Allergan Plc 106

Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc 106

Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc 107

Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH 107

Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc 108

Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV 108

Bone Marrow Transplant Rejection - Pipeline by Athersys Inc 109

Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc 109

Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Ltd 110

Bone Marrow Transplant Rejection - Pipeline by Biogen Inc 110

Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company 111

Bone Marrow Transplant Rejection - Pipeline by Cantex Pharmaceuticals Inc 111

Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc 112

Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc 112

Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA 113

Bone Marrow Transplant Rejection - Pipeline by CellECT Bio Inc 113

Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs Inc 114

Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd 114

Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Limited 115

Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc 115

Bone Marrow Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 116

Bone Marrow Transplant Rejection - Pipeline by Dr. Falk Pharma GmbH 116

Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics Inc 117

Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd 117

Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics Inc 118

Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corp Ltd 118

Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences Inc 119

Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc 119

Bone Marrow Transplant Rejection - Pipeline by Immunomedics Inc 120

Bone Marrow Transplant Rejection - Pipeline by Incyte Corp 120

Bone Marrow Transplant Rejection - Pipeline by Jazz Pharmaceuticals Plc 121

Bone Marrow Transplant Rejection - Pipeline by Kadmon Corp LLC 121

Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd 122

Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma NV 122

Bone Marrow Transplant Rejection - Pipeline by Kymab Ltd 123

Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co Ltd 123

Bone Marrow Transplant Rejection - Pipeline by MacroGenics Inc 124

Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc 124

Bone Marrow Transplant Rejection - Pipeline by Medsenic 125

Bone Marrow Transplant Rejection - Pipeline by Mesoblast Ltd 125

Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc 126

Bone Marrow Transplant Rejection - Pipeline by Nektar Therapeutics 126

Bone Marrow Transplant Rejection - Pipeline by Neovii Pharmaceuticals AG 127

Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc 127

Bone Marrow Transplant Rejection - Pipeline by Novartis AG 128

Bone Marrow Transplant Rejection - Pipeline by OncoImmune Inc 128

Bone Marrow Transplant Rejection - Pipeline by OSE Immunotherapeutics 129

Bone Marrow Transplant Rejection - Pipeline by Pfizer Inc 129

Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co Ltd 130

Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc 130

Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corp 131

Bone Marrow Transplant Rejection - Pipeline by Sanofi 131

Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics Inc 132

Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics Inc 132

Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics Inc 133

Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Ltd 133

Bone Marrow Transplant Rejection - Pipeline by Synedgen Inc 134

Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies Inc 134

Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Ltd 135

Bone Marrow Transplant Rejection - Pipeline by Targazyme Inc 135

Bone Marrow Transplant Rejection - Pipeline by United BioPharma Inc 136

Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc 136

Bone Marrow Transplant Rejection - Pipeline by VBI Vaccines Inc 137

Bone Marrow Transplant Rejection - Pipeline by Xenikos BV 137

Bone Marrow Transplant Rejection - Pipeline by XL-protein GmbH 138

Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology Inc 138

Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc 139

Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc 139

Graft Versus Host Disease (GVHD) - Pipeline by Allergan Plc 140

Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc 140

Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc 141

Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH 141

Graft Versus Host Disease (GVHD) - Pipeline by Aptevo Therapeutics Inc 142

Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV 142

Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc 143

Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc 143

Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Ltd 144

Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc 144

Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company 145

Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc 145

Graft Versus Host Disease (GVHD) - Pipeline by Cell2B Advanced Therapeutics SA 146

Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio Inc 146

Graft Versus Host Disease (GVHD) - Pipeline by Commence Bio Inc 147

Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd 147

Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc 148

Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH 148

Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics Inc 149

Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd 149

Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc 150

Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corp Ltd 150

Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences Inc 151

Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc 151

Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp 152

Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc 152

Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corp LLC 153

Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd 153

Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma NV 154

Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd 154

Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co Ltd 155

Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics Inc 155

Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc 156

Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd 156

Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc 157

Graft Versus Host Disease (GVHD) - Pipeline by Nektar Therapeutics 157

Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc 158

Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG 158

Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune Inc 159

Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics 159

Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc 160

Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co Ltd 160

Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp 161

Graft Versus Host Disease (GVHD) - Pipeline by Sanofi 161

Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics Inc 162

Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics Inc 162

Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc 163

Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Ltd 163

Graft Versus Host Disease (GVHD) - Pipeline by Synedgen Inc 164

Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Ltd 164

Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc 165

Graft Versus Host Disease (GVHD) - Pipeline by TC BioPharm Ltd 165

Graft Versus Host Disease (GVHD) - Pipeline by TxCell SA 166

Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc 166

Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc 167

Graft Versus Host Disease (GVHD) - Pipeline by VBI Vaccines Inc 167

Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV 168

Graft Versus Host Disease (GVHD) - Pipeline by XL-protein GmbH 168

Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology Inc 169

Liver Transplant Rejection - Pipeline by Astellas Pharma Inc 170

Liver Transplant Rejection - Pipeline by Biogen Inc 170

Liver Transplant Rejection - Pipeline by Conatus Pharmaceuticals Inc 171

Liver Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 171

Liver Transplant Rejection - Pipeline by Novartis AG 172

Liver Transplant Rejection - Pipeline by RedHill Biopharma Ltd 172

Kidney Transplant Rejection - Pipeline by Amgen Inc 173

Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp 173

Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc 174

Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc 174

Kidney Transplant Rejection - Pipeline by Biogen Inc 175

Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc 175

Kidney Transplant Rejection - Pipeline by Corline Biomedical AB 176

Kidney Transplant Rejection - Pipeline by CSL Ltd 176

Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc 177

Kidney Transplant Rejection - Pipeline by Grifols SA 177

Kidney Transplant Rejection - Pipeline by Hansa Medical AB 178

Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd 178

Kidney Transplant Rejection - Pipeline by Magnus Life Ltd 179

Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG 179

Kidney Transplant Rejection - Pipeline by Novartis AG 180

Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd 180

Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics 181

Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd 181

Kidney Transplant Rejection - Pipeline by Pharming Group NV 182

Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC 182

Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc 183

Kidney Transplant Rejection - Pipeline by Shire Plc 183

Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc 184

Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH 185

Lung Transplant Rejection - Pipeline by Dompe Farmaceutici SpA 185

Lung Transplant Rejection - Pipeline by Kamada Ltd 186

Lung Transplant Rejection - Pipeline by Novartis AG 186

Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc 187

Heart Transplant Rejection - Pipeline by Astellas Pharma Inc 187

Heart Transplant Rejection - Pipeline by Heat Biologics Inc 188

Heart Transplant Rejection - Pipeline by Noxxon Pharma AG 188

Bone Marrow Transplant Rejection - Dormant Projects 189

Graft Versus Host Disease (GVHD) - Dormant Projects 192

Liver Transplant Rejection - Dormant Projects 195

Kidney Transplant Rejection - Dormant Projects 196

Lung Transplant Rejection - Dormant Projects 198

Heart Transplant Rejection - Dormant Projects 198

Bone Marrow Transplant Rejection - Discontinued Products 199

Graft Versus Host Disease (GVHD) - Discontinued Products 199

Liver Transplant Rejection - Discontinued Products 200

Kidney Transplant Rejection - Discontinued Products 200

List Of Figures, Charts and Diagrams
in Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017]

List of Figures

Number of Products under Development for Bone Marrow Transplant Rejection 16

Number of Products under Development by Companies, Bone Marrow Transplant Rejection 17

Number of Products under Development by Universities/Institutes, Bone Marrow Transplant Rejection 20

Number of Products under Development for Graft Versus Host Disease (GVHD) 27

Number of Products under Development by Companies, Graft Versus Host Disease (GVHD) 28

Number of Products under Development by Universities/Institutes, Graft Versus Host Disease (GVHD) 31

Number of Products under Development for Liver Transplant Rejection 38

Number of Products under Development by Companies, Liver Transplant Rejection 39

Number of Products under Development by Universities/Institutes, Liver Transplant Rejection 40

Number of Products under Development for Kidney Transplant Rejection 42

Number of Products under Development by Companies, Kidney Transplant Rejection 43

Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 45

Number of Products under Development for Lung Transplant Rejection 48

Number of Products under Development by Companies, Lung Transplant Rejection 49

Number of Products by Top 10 Targets, Bone Marrow Transplant Rejection 52

Number of Products by Stage and Top 10 Targets, Bone Marrow Transplant Rejection 52

Number of Products by Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection 55

Number of Products by Stage and Top 10 Mechanism of Actions, Bone Marrow Transplant Rejection 55

Number of Products by Routes of Administration, Bone Marrow Transplant Rejection 58

Number of Products by Stage and Routes of Administration, Bone Marrow Transplant Rejection 58

Number of Products by Top 10 Molecule Types, Bone Marrow Transplant Rejection 60

Number of Products by Stage and Top 10 Molecule Types, Bone Marrow Transplant Rejection 60

Number of Products by Top 10 Targets, Graft Versus Host Disease (GVHD) 62

Number of Products by Stage and Top 10 Targets, Graft Versus Host Disease (GVHD) 62

Number of Products by Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD) 65

Number of Products by Stage and Top 10 Mechanism of Actions, Graft Versus Host Disease (GVHD) 65

Number of Products by Routes of Administration, Graft Versus Host Disease (GVHD) 68

Number of Products by Stage and Routes of Administration, Graft Versus Host Disease (GVHD) 68

Number of Products by Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 70

Number of Products by Stage and Top 10 Molecule Types, Graft Versus Host Disease (GVHD) 70

Number of Products by Top 10 Targets, Liver Transplant Rejection 72

Number of Products by Stage and Top 10 Targets, Liver Transplant Rejection 72

Number of Products by Top 10 Mechanism of Actions, Liver Transplant Rejection 74

Number of Products by Stage and Top 10 Mechanism of Actions, Liver Transplant Rejection 74

Number of Products by Routes of Administration, Liver Transplant Rejection 76

Number of Products by Stage and Routes of Administration, Liver Transplant Rejection 76

Number of Products by Molecule Types, Liver Transplant Rejection 78

Number of Products by Stage and Molecule Types, Liver Transplant Rejection 78

Number of Products by Top 10 Targets, Kidney Transplant Rejection 80

Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection 80

Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection 82

Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection 82

Number of Products by Routes of Administration, Kidney Transplant Rejection 84

Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection 84

Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection 86

Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection 86

Number of Products by Targets, Lung Transplant Rejection 88

Number of Products by Stage and Targets, Lung Transplant Rejection 88

Number of Products by Top 10 Mechanism of Actions, Lung Transplant Rejection 90

Number of Products by Stage and Top 10 Mechanism of Actions, Lung Transplant Rejection 90

Number of Products by Routes of Administration, Lung Transplant Rejection 92

Number of Products by Stage and Routes of Administration, Lung Transplant Rejection 92

Number of Products by Molecule Types, Lung Transplant Rejection 94

Number of Products by Stage and Molecule Types, Lung Transplant Rejection 94

Number of Products by Targets, Heart Transplant Rejection 96

Number of Products by Stage and Targets, Heart Transplant Rejection 96

Number of Products by Mechanism of Actions, Heart Transplant Rejection 98

Number of Products by Stage and Mechanism of Actions, Heart Transplant Rejection 98

Number of Products by Routes of Administration, Heart Transplant Rejection 100

Number of Products by Stage and Routes of Administration, Heart Transplant Rejection 100

Number of Products by Molecule Types, Heart Transplant Rejection 102

Number of Products by Stage and Routes of Administration, Heart Transplant Rejection 102

Additional Details

Publisher

GBI Research

Publisher Information

Reference

100094 |

Number of Pages

242

Report Format

PDF

GBI Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Transplantation Partnering 2010 to 2017
The Global Transplantation Partnering Terms and Agreements since 2010 report provides understanding ...
01 Feb 2017 by Current Partnering USD $1,495 More Info
Cartilage Repair/ Cartilage Regeneration Market by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), Region - Forecast to 2021
The global cartilage repair/ cartilage regeneration market is projected to reach USD 779.8 million b...
05 Dec 2016 by MarketsandMarkets USD $5,650 More Info
Global Transplantation Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Transplantation Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
SAVE 15% today! Stem Cell Transplantation Global Clinical Trials Review, H2, 2016
Stem Cell Transplantation Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
30 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Stem Cell Transplantation Global Clinical Trials Review, H2, 2016
Stem Cell Transplantation Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
30 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
Transplantation Diagnostics Global Market - Forecast to 2022
Transplantation is a surgical procedure of transferring organ, tissue or cell taken from one part of...
25 Aug 2016 by IQ4I USD $4,500 More Info
Transplantation Diagnostics Global Market - Forecast to 2022
Transplantation is a surgical procedure of transferring organ, tissue or cell taken from one part of...
25 Aug 2016 by IQ4I USD $4,500 More Info
Transplantation Diagnostics Global Market - Forecast to 2022
Transplantation is a surgical procedure of transferring organ, tissue or cell taken from one part of...
25 Aug 2016 by IQ4I USD $4,500 More Info
SAVE 15% today! Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2015
Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2015SummaryGlobalData's c...
30 Dec 2015 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by GBI Research

Download Free Report Summary PDF

Transplantation Drug Development Pipeline Review, 2017 [Report Updated: 01-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data